Featured Opinions
The economics of patient compliance
by Anonymous (not verified)
by WendyB
I was amazed recently at the level of response to a small post on my "other" blog on the subject of Twitter.
I don't care! - relationships are overrated
by Baba Awopetu
Relationships do not matter, at least not as much as we make out. We should put more effort in to doing good things and talking about it i.e. strong propositions and communications.
Patient Compliance- What's The Big Deal?
Being a Mum to a 16month old, I have spent much more time in a doctor's surgery over the past year than at any other point in my life. And, I have met my fair share of doctors.
by Baba Awopetu
We all have a plan... but now, more than ever, our plans are facing a real test. For those who perform yearly rituals mislabelled as planning, the game is up.
Wherever I go, whoever I talk to there seems to be no consistent or very successful strategies for dealing with poor patient adherence/compliance.
by Mark Wayland
Reading the latest sad and depressing news about Pfizer brought a past experience back vividly into my mind.
Economic crisis: bane or boon for emarketing?
by Anonymous (not verified)
It took a while before pharma started to embrace the digital world as a (future) component of its go-to-market strategy, but in 2008, many companies finally started to get high-visibility strategic pr
Healthcare arena and the downturn
by Baba Awopetu
Marketers, like other functions, are being asked to do more with less. Since it is not possible to do more of the same with fewer resources, it is crucial that we do the right things.
Segmentation in the pharmaceutical arena is a myth: most talk about it, but very few do it. Now is the time to adopt this arguably most fundamental principle of marketing in practice.
We are obsessed with branding, rather than the critical art of brand building. However, this subtle difference in terminology has a huge impact on our business.
Patient flow in Oncology - The most complex market of them all?
by Fitall in DC
Oncology is quite probably the most complex health care market, and modeling it has become an essential need for most players.
The Intelligence of Intelligence
by Anonymous (not verified)
The Business and Competitive Intelligence functions in Pharma generally fly under the radar of noticeability to those looking at the industry, They generally remain in the shadow of the 'glory' sales,
Pharma Acquisitions- What will happen this year?
by Anonymous (not verified)
Valeant Pharmaceuticals International today announced over the Christmas Break that the company completed its acquisition of Dow Pharmaceutical Sciences, Inc, a privately held dermatology company that
Good intentions, excellent execution poor communication
by Anonymous (not verified)
Coordinating partnerships between the USA and the European Union
by pierremorgon
US based specialty care companies are reluctant to approach the fragmented and multi lingual regulatory and market access procedures as well as the complex marketing and distribution situations requir
The Downside of the Power of Social Media
by WendyB
Someone pointed me to this post the other day on YouTube: http://uk.youtube.com/watch?v=02krhNFfEq4
REMS - The acronym that will change your life
by Fitall in DC
In 2007 the FDA was re-authorized with a significant new authority - the authority to require the establishment of Risk Evaluation and Mitigation Strategies - REMS. In a very short part of the reauthorization bill the entire world of marketing drugs in the USA was turned upside down - and not much has been said about it!
Your Yearly Sales Coaching Report Card 2
by Mark Wayland
Here's 2 more aspects of Sales Coaching to review.